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Summary The neurotransmitter glutamate plays a pivotal role in the development of the
neuropathological sequelae following acute seizures. Our previous data proved the efficacy of
the NMDA-receptor antagonists on the symptoms, survival and neuronal activation in the 4-
aminopyridine- (4-AP) induced seizures. In this study, we examined the effects of two different
doses of a non-competitive, selective, allosteric AMPA-receptor antagonist, GYKI 52466. GYKI
52466 was effective in prolonging the latency to generalised seizures and reduction of seizure
mortality. However, the effects on neuronal c-fos expression and astrocyte swelling were com-
plex. The 25mg/kg dose of GYKI 52466 was effective in reducing the c-fos immunoreactivity
(IR) in the hippocampus only. In the neocortex the overall c-fos-IR cell counts were increased
significantly. Investigation of the neocortical parvalbumin-containing interneuron population
proved that GYKI 52466 decreased c-fos expression. The 50mg/kg dose of GYKI 52466 signifi-
cantly reduced the c-fos-IR in the neo- and allocortex, not only in principal neurons, but also
in the parvalbumin-positive interneurons. The GYKI 52466-pretreatment did not prevent the
astrocyte swelling in the investigated cortical areas; thus we conclude that the AMPA-receptors
have little if any involvement in the in the mediation of neuropathological alterations in acute
convulsions.
© 2007 Elsevier B.V. All rights re
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. Introductionhe excessive, pathologic oversynchronisation (Perrault and
voli, 1991; Yang and Benardo, 2002) of neuronal activ-
ty and the disequilibrium between certain excitatory and
nhibitory factors (Gulya´s-Kova´cs et al., 2002; Schwaller
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et al., 2004) are considered as the pathophysiologic basis
of the epileptiform activity in the central nervous sys-
tem. The conventional therapeutic regimes concentrate
on the strengthening of the inhibitory neurotransmis-
sion (MacDonald et al., 1985; Lukasiuk and Pitka¨nen,
2000) whereas the inhibition of the excitatory responses
is under current research, but results are mainly avail-
able about the role of NMDA-mediated events (Conti and
Weinberg, 1999; Borowicz et al., 2001; Szaka´cs et al.,
2003).
One of the well-known (Miha´ly et al., 1990; Pen˜a
and Tapia, 2000) chemical means to elicit acute seizures
with generalised tonic-clonic features in an in vivo
animal model is the 4-aminopyridine (4-AP), having well-
circumscribed pharmacokinetic (Lemeignan et al., 1984;
Berger et al., 1989) and pharmacodynamic (Perrault and
Avoli, 1991; Miha´ly et al., 2000) properties. 4-AP is a
nitrogen-containing heterocyclic K+-channel blocker, exert-
ing its effect mainly via IK(A) and IK(V) channel types
(Bru¨ckner and Heinemann, 2000), thus the shift of the
membrane potential towards depolarisation enables Ca2+-
influx; mainly via voltage-gated Ca2+-channels and the
NMDA-receptor ion channels (Greenberg and Ziff, 2001), the
latter are opened by the mainly presynaptically acting 4-
AP-induced membrane-depolarisation (Yang and Benardo,
2002). The sustained, repeated, synchronised neuronal dis-
charge, the so-called ‘‘burst firing’’ is a basic feature of
the central nervous system seizure mechanism (Labiner
et al., 1993). The prolonged neuronal depolarisation stim-
ulates both excitatory and inhibitory neurotransmitter
release (Versteeg et al., 1995), especially glutamate (Pen˜a
and Tapia, 1999; Kova´cs et al., 2003) and reinforces
the inhibitory (IPSPs) and excitatory postsynaptic poten-
tials (EPSPs) (Perrault and Avoli, 1991). On the basis of
the electrophysiological investigations (Yang and Benardo,
2002), one of the 4-AP-induced cortical spontaneous dis-
charge components can be blocked by glutamate receptor
antagonists, whereas the other type by GABAA receptor
antagonists, suggesting that it was produced by the syn-
chronisation of GABAergic (GABA, -amino-butyric acid)
interneurons.
The immediate early gene (IEG) c-fos (Morgan and
Curran, 1991) is an inducible transcription factor (ITF) play-
ing important role in certain nuclear regulative processes
(Dragunow et al., 1989). The gene products of the IEGs,
via transcriptional regulation influence the genes involved in
the maturation and adaptation mechanisms of the nervous
system (Retchkiman et al., 1996; Schmoll et al., 2001), or in
plasticity and neurodegeneration (Herdegen and Waetzig,
2001), as well as in epilepsy (Gass et al., 1992; Rocha
et al., 1999). The c-fos mRNA transcription shows strict
correlation with the electrophysiologically proven cellular
activity (Labiner et al., 1993), and this correspondence
establishes the Fos protein (appearing in the cell nuclei
of the neurons concerned) as a sensitive marker of the
increase of neuronal activity (Hoffmann and Lyo, 2002).
NMDA- and AMPA-receptors are amongst the external sig-
nals, which activate c-fos transcription (Herdegen and Leah,
1998).
Amongst the earliest neuropathological changes in
seizure activity (Kelso and Cock, 2004), the swelling of the
astrocytic processes has already been observed (Fujikawa
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t al., 1992; Fabene et al., 2006). Astrocytes are the main
ell types that swell in cytotoxic brain oedema (Kimelberg,
004), especially the pericapillary foot processes, which are
he predominant sites of aquaporin-4 (AQP4) expression in
he brain (Papadopoulos and Verkman, 2007). Glutamate,
t similar concentrations required to induce neuronal cell
eath, has been shown to increase cell volume in cul-
ured astrocytes (Han et al., 2004). The astrocytic swelling
as numerous deleterious secondary effects, such as the
elease and decreased uptake of excitatory amino acids
Kimelberg, 2004); worsening the micro-environmental cir-
umstances like a circulus vitiosus process. Pharmacological
nhibition of seizure activity decreases brain oedema in dif-
erent animal models (Clifford et al., 1990; Tian et al.,
005).
The GYKI 52466 (1-(4-aminophenyl)-4-methyl-7,8-
ethylenedioxy-5H-2,3-benzodiazepine hydrochloride) is a
elective, non-competitive, presumably allosteric antago-
ist of the AMPA-(-amino-3-hydroxy-5-methyl-4-isoxazol
ropionate)-subtype ionotropic glutamate receptors
Donevan and Rogawski, 1998; Arai, 2001); with good
lood—brain-barrier (BBB) permeability (Barna et al., 2000),
europrotective effects in seizure and cerebral ischaemia
Szabados et al., 2001; Arias et al., 1999), antinociceptive
nd anti-inflammatory properties (Sze´kely et al., 1997;
zabados et al., 2001) and has other advantageous effects
n ischaemic conditions (Block et al., 1996; Arias et al.,
999). Electrophysiological investigations (Paternain et al.,
995; de Sarro et al., 1995) proved the antagonistic activ-
ty of GYKI 52466 upon the AMPA- and kainate-receptors,
hereas practically no effect has been demonstrated on the
MDA-receptors, metabotropic glutamate receptors, and
n the GABAA-receptors. According to the kinetic analysis
f AMPA-receptors, the most likely way of GYKI 52466 effect
s elongating the desensitisation—resensitisation process,
he channel closing frequency and the deactivation (Arai,
001).
In our former studies (Szaka´cs et al., 2003) the
MDA-subtype ionotropic glutamate receptor antagonists
n pretreatment significantly decreased the expression
f c-fos in the examined neo- and allocortical areas in
he 4-aminopyridine acute convulsive rat model; and in
he same time, the symptoms of seizure were elimi-
ated, as well. NMDA-antagonists significantly decreased
eizure-related astrocyte swelling in the cerebral cor-
ex (Za´dor and Weiczner, unpublished). The aim of the
resent study was to assess the antagonism of another
ell-characterised (Alexander and Peters, 2000) glutamate
eceptor, the AMPA-receptor in a similar paradigm. Accord-
ng to the time-course of the GYKI 52466 anticonvulsive
fficacy (Lees and Leong, 2001; Jakus et al., 2004), and
ased on our preliminary data we focused on the inves-
igation of the short-term effects (c-fos expression and
ericapillary astrocyte swelling) within the very first hour
f seizure initiation. To evaluate the activation status
hanges of the inhibitory cells in the 4-AP paradigm,
e also investigated the effect of the AMPA-receptor
ntagonism by assessing the c-fos expression pattern of
he immunohistochemically well-detectable parvalbumin
PV)-positive cells (Schwaller et al., 2004) represent-
ng a subpopulation of GABAergic interneurons (DeFelipe,
997).
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. Materials and methods
.1. Animals and treatment
he animal experiments were conducted in accordance with
revailing laws and ethical considerations (European Community
ouncil Directive of 24 November 1986 (86/609/EEC) and the
ungarian Animal Act (1998). Written permission was obtained in
dvance from the Faculty Ethical Committee on Animal Experiments
University of Szeged). The animals were maintained under stan-
ard animal housing conditions, with ad libitum access to food and
ater. The experiments were performed onmaleWistar rats weight-
ng 200—250 g. The convulsant agent 4-aminopyridine (4-AP; Sigma,
t. Louis, MO) was dissolved in physiologic saline (0.67mg in 1ml
ehicle) and administered intraperitoneally (i.p.), in 5mg/kg dose.
n previous investigations (Miha´ly et al., 1990), this dosage proved to
e convulsant. The non-competitive AMPA-receptor antagonist GYKI
2466 (IVAX GYKI Co. Ltd., Budapest, Hungary) was dissolved in 50%
MSO (de Sarro et al., 1995) (dimethyl-sulphoxide; Sigma, St. Louis,
O) dilution (3.33 or 6.67mg in 1ml vehicle), and administered i.p.
n 25 or 50mg/kg dose, respectively.
.2. Experimental procedure
he animals were randomly divided into three groups. In the first
groups, the animals (10 per group) were pretreated with 25 or
0mg/kg GYKI 52466, respectively. 15min later, the convulsant
mg/kg 4-AP was administered. The control group (10 animals)
eceived the solvent of GYKI 52466 and 5mg/kg 4-AP. The experi-
ents were finished 1 h after the 4-AP injection, within the range of
he presumed maximal anticonvulsive effect of the GYKI 52466 (de
arro et al., 1998.). At the end of the experiments, the animals were
eeply anaesthetised with diethyl-ether and perfused transcar-
ially with 250ml of 0.1M phosphate-buffered saline (PBS) pH 7.4;
ollowed by 300ml of fixative (four animals randomly for immuno-
istochemistry: 4% phosphate-buffered paraformaldehyde, pH 7.4;
our animals randomly for electron microscopy: 1% paraformalde-
yde and 1% glutaraldehyde in phosphate-buffered solution, pH
.4). In case of the brains for immunohistochemistry, they were
apidly removed, postfixed in 4% paraformaldehyde for 1 h, and then
ryoprotected overnight (30% sucrose in 0.1M phosphate buffer, pH
.4) at room temperature. Serial frozen sections were cut on a cryo-
tat (Reichert-Jung Cryocut 1800) in the coronal plane at a thickness
f 24m and every third section was processed for immunohisto-
hemistry (2.3). In case of the brains for electron microscopy, they
ere rapidly removed, and then we followed the routine procedure
s described below in Section 2.4.
.3. Immunohistochemistry
n the coronal brain slices c-fos and parvalbumin double-labelling
mmunohistochemistry was carried out. The sections were pre-
reated with Triton X-100 and H2O2 (9:1) solution, then they
ere incubated in 20% normal pig serum, avidin and biotin; then
n the primary antibody cocktail with c-fos antibody (1:2000;
aised in rabbit, Santa Cruz Biotechnology, CA) and parvalbu-
in (1:60,000; raised in mouse, Sigma—Aldrich). The secondary
ntibody cocktail contained biotinylated goat-anti-rabbit (B-GAR,
:400; Jackson ImmunoResearch, PA) and goat-anti-mouse (GAM,
:400; Jackson ImmunoResearch, PA) antibodies. The tertiary anti-
odies were STA-PER (1:1000, Jackson ImmunoResearch, PA) and
ouse-PAP (1:1000, Jackson ImmunoResearch, PA). The peroxidase
eactions were localised with diaminobenzidine tetrahydrochlo-
ide (Sigma—Aldrich) with nickel chloride, yielding black reaction
roduct (c-fos) or without nickel chloride, yielding brown reaction
roduct (parvalbumin).
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.4. Electron microscopy
amples of the right parietal neocortex and hippocampus were
repared for electron microscopy. The tissue blocks were incu-
ated in an aqueous solution of 1% OsO4 and 5% K2Cr4O7 (1:1)
fter thorough rinsing. The samples were dehydrated, incubated in
% uranyl-acetate and embedded in Durcupan epoxy resin (Fluka,
uchs, Switzerland). Semithin sections were cut on an ultramicro-
ome (Ultracut E, Reichert-Jung, Vienna, Austria) and stained on
bject glasses with a 1:1 mixture of 1% methylene blue and 1%
zure II blue. The samples were then coverslipped with DPX and
nalysed under a light microscope (Nikon E600, Nikon Co., Tokyo,
apan). Ultrathin sections were cut of the same blocks and collected
n 200 mesh copper grids. The preparations were then contrasted
ith 5% uranyl-acetate and Reynolds lead-citrate solution. Finally,
he samples were analysed by a Philips TM10 transmission elec-
ron microscope (Eindhoven, Netherlands). Photographs were taken
ith a computer assisted digital camera (MegaView II, Soft Imaging
ystems, Mu¨nster, Germany).
.5. Analysis of the behavioural data
he behavioural outcome (effects concerning seizure activity and
ossible adverse effects) of the pretreatment with the AMPA-
ntagonist was observed up to 1 h after the 4-AP injection. The
nset of the GTCS was always sudden and clear-cut, so the latency
from the 4-AP injection) of GTCS was easily measurable. The GTCS
atency was statistically evaluated with one-way analysis of vari-
nce (ANOVA) followed by the Bonferroni post hoc test (significance
riterion was 0.05). The GTCS occurrence and overall mortality data
ere analysed with the Fisher’s exact probability test (significance
riterion was 0.05). The statistical analysis was performed with the
PSS 9.0 software.
.6. Analysis of the immunohistochemical data
uantitative analysis was performed on five sections per animal
N = 4; the mean data per each animal was used in the statistical
nalysis), selected from every brain on the basis of the same stereo-
axic coordinates (Paxinos and Watson, 1998). Areas of interests
AOIs) for counts of immunostained neuronal nuclei were selected
orm the S1Tr region of the parietal neocortex, regions CA1, CA2
nd CA3 of the Ammon’s horn and from the hilus and granule cell
ayer of the dentate gyrus. Within every AOI, the immunoreactive
IR) cells (cell nuclei for c-fos and cells for PV) were counted using
NIKON Eclipse 600 microscope equipped with a SPOT RT Slider
igital camera (1600× 1200 dpi in 8 bits), using the Image Pro Plus
morphometric software (Media Cybernetics, Silver Spring, MD).
ollowing background subtraction, the threshold was determined
o that all labelled nuclei could be recognised. The counting was
erformed blindly of the animal’s treatment. The AOIs were deter-
ined using the rectangular field of the camera. In the neocortex,
ell counts were done using a 10× objective, and the AOI (an area
f 1.2mm2) included all neocortical layers (I-VI) from the pia mater
o the subcortical white matter. Cell counts were then normalised
o 1mm2. In the hippocampus, cell counts were done using a 40×
bjective, and were again normalised to 1mm2. In regions CA1-
, the AOI (an area of 0.05mm2) included the stratum pyramidale
nd a narrow zone of the strata oriens and radiatum. The hilus of
he dentate gyrus was outlined according to Amaral (1978), and
ounting was performed. The whole extent of the upper and lower
lades of the dentate granule cell layer was outlined and used as
OI, and labelled cell nuclei were counted in this area. The quanti-
ative assessment of the parvalbumin-positive cells was omitted in
he granular layer of the dentate gyrus, due to the many, strongly c-
os immunoreactive cell nuclei. The data were analysed statistically
omparing sets of findings with the same magnification. Differences
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in the number of c-fos positive or c-fos and parvalbumin double-
positive cells in the control and in the antagonist-pretreated were
analysed with one-way analysis of variance (ANOVA), followed by
the Bonferroni post hoc test. A significance criterion of 0.05 was
used. The statistical analysis was performed with the SPSS 9.0 soft-
ware.
2.7. Analysis of the electron microscopical data
Approximately 900m2 of sample surface was viewed systemati-
cally through all neocortical layers of the parietal cortex or in the
hippocampus; four EM preparates per animal (N = 4) was examined
and the mean data of the altogether 14± 2 capillary cross sec-
tions per each animal was used in the statistical analysis. The total
area of the so-called neurovascular unit was measured which con-
sists of the capillary lumen, the surrounding endothelium and the
astrocytic end-feet covering the basal lamina of the microvascular
endothelium. (Image Pro Plus 4.5 morphometric software; Media
Cybernetics, Silver Spring, MD, USA). One-way analysis of variance
(ANOVA) followed by the Bonferroni post hoc test (significance cri-
terion: p < 0.05; SPSS 9.0 statistical software) was performed on
the measured area data (area of capillaries, area of the swollen
pericapillary astrocytic endfeet).
3. Results
3.1. Behavioural analysis
The i.p. administration of 4-AP causes characteristic
behavioural symptoms within 15—20min (Miha´ly et al.,
1990): increased exploratory activity, tremor of the vibrissal
and masticatory muscles, followed by generalised tremor of
the body musculature, observable as continuous fascicula-
tion of the muscles, the more and more frequent clonuses
and tonus changes of the limbs. Abduction of the poste-
rior limbs and a fan-like abduction of the fingers are also
observable. The increasing motor symptoms lead to a ‘‘wild
running’’ phenomenon and, finally, to generalised tonic-
clonic seizures (GTCS), often preceded by vocalisation. The
limbs are extended; hypersalivation and release of excreta
are regular. With the dissipation of the tonic component,
the clonic one becomes more dominant for a while with
tenebrosity (post-convulsive state with limited cognitive and
motor activity) for other 10—15min until regaining normal
activity. In some cases the GTCS may occur once more. The
gradual dissipation of the seizure activity can be detected
electrophysiologically after 50—60min (Miha´ly et al., 2005);
90—100min after the 4-AP injection, the animals recover.
Nevertheless, approximately 20% of the control group ani-
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Table 1 Behavioural analysis of the effect of the AMPA-receptor
Pretreatment Treatment Mean G
latenc
vehicle of GYKI 52466 i.p. 5mg/bw kg 4-AP i.p. 26.60
25mg/bw kg GYKI 52466 i.p. 5mg/bw kg 4-AP i.p. 49.57*
50mg/bw kg GYKI 52466 i.p. 5mg/bw kg 4-AP i.p. 46.75*
The observation was made with 10 animals in each group. The GTC
from the administration time of the 4-AP injection. Mean GTCS latenc
(vehicle + 4-AP). *p < 0.05 ANOVA followed by the Bonferroni post hoc
the significant difference vs. control group (vehicle + 4-AP). p < 0.05 F25
als die during or after GTCS, due to the seizure. The
nset of the GTCS was always sudden and clear-cut, so the
atency (from the 4-AP injection) of GTCS was easily mea-
urable.
The increase in the GTCS latencies of the GYKI 52466-
retreated groups is observable but statistically do not
iffer between the two dose groups, however, they repre-
ent a significant change compared with the control group
Table 1). In the pretreated groups, the GTCS occurred in
0% (25mg/kg) or in 10% (50mg/kg) of the animals, whilst
n 80% of the 4-AP control animals (without GYKI 52466
retreatment). According to the Fisher’s exact probability
est, reduction in the number of animals (in which a GTCS
ccurred) in both groups administered GYKI was statisti-
ally significantly different from the number in the vehicle
reated group. Nevertheless, there is no significant differ-
nce between the groups with different GYKI 52466 doses.
uring the 1-h observation, no recurrent GTCS was observed,
he survival ratio was 100% in both pretreated groups, whilst
0% in the control group; which is, however, statistically not
ignificant. Besides the local — presumably peritoneal — irri-
ation (at the site of injection) dissipating within 1—2min
fter the DMSO administration (as vehicle in the control
roup), no long-lasting side-effect of DMSO was noted, the
nimals displayed normal activity. As observable side-effects
f the GYKI 52466 pretreatment, transient (approximately
5—20min before regaining normal activity) ataxia, loss
f coordination and reduction of the locomotor activity,
ogether with apparently sedative effect (decreased vigi-
ance) were noted (i.e. the animals stopped the explorative
ovements, laid down at the floor of the cage, breath-
ng evenly similar to sleeping, their overall muscle tone
ppeared to be reduced at holding or palpating the animals).
hese changes were pure visual observations; no methodical
valuation was performed on these parameters.
.2. Immunohistochemistry
he lower dose GYKI 52466 pretreatment (25mg/kg) signif-
cantly increased, whereas the higher dose pretreatment
50mg/kg) significantly decreased the number of c-fos-IR
ell nuclei in the neocortex (Fig. 1). In laminar distribu-
ion, the laminae II—III and V—VI showed this significant
ecrease with the higher dose (the decrease in the lam-
na IV was not significant). The lower dose pretreatment
ielded significant increase only in the lamina V, the other
hanges are statistically not significant. In the lamina I, no
hange was detectable in both cases. As for the c-fos and PV
antagonism on 4-AP seizures
TCS
y (min)
S.E.M. Animals displaying
GTCS (%)
Mortality (%)
1.81 80 20
2.31 20 0
4.21 10 0
S (i.e. generalised tonic-clonic seizure) latency was measured
y: asterisk indicates the significant difference vs. control group
test. Seizure occurrence and mortality: black triangle indicates
isher’s exact probability test.
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Fig. 1 Effect of GYKI 52466 on the c-fos gene expression in the neocortex. (A—C) Representative immunohistochemical images
illustrating the c-fos and c-fos + parvalbumin (PV) immunolabelled neurons in the neocortex of the experimental animals. Animals
with vehicle + 5mg/kg 4-AP (control) (A); 25mg/kg GYKI 52466 + 5mg/kg 4-AP (gyki25) (B) and 50mg/kg GYKI 52466 + 5mg/kg 4-AP
(gyki50) (C) treatment, respectively (N = 4 per group). Roman numerals indicate the neocortical laminae. Bar: 250m. Magnification:
40×. (D—G) Statistical evaluation of the c-fos (D—E) and c-fos and parvalbumin (F—G) immunoreactive cell counts pro square
millimetre (sq mm), in all layers (D and F) and in laminar distribution (E and G); comparison of the data from pretreated (with 25
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ir 50mg/kg GYKI 52466 before 5mg/kg 4-AP, respectively) and
nduction. Asterisks denote the significant differences (with vs
est, p < 0.05; S.E.M. is indicated in every case).
ouble-positive cells, the lower dose pretreatment had no
ffect while the higher dose pretreatment caused a signif-
cant decrease in the double-immunoreactive cell counts.
his change was significant only in the lamina II for the
ower dose, whereas in the laminae II—VI for the higher dose
retreatment. In the hippocampal sectors CA1-3 and in the
ilus of the dentate gyrus even the lower dose GYKI 52466
retreatment caused significant reduction not only in the
umber of the c-fos-IR cell nuclei; but also in the number of
he double-labelled cells (Fig. 2). This c-fos-IR count change
s even more pronounced in the granular layer of the dentate
yrus: control c-fos-IR nuclei (3535/mm2; 100%) versus GYKI
2466-pretreatment with 25mg/kg (1401/mm2; 39.6% of the
ontrol) or with 50mg/kg (184/mm2; 5.2% of the control).
.3. Electron microscopy
n the case of the neocortical capillary areas (Fig. 3), there
as no significant difference amongst the 4-AP control and
he GYKI 52466-pretreated groups. Measuring the hippocam-
al capillary areas (Fig. 4), there was a significant difference
etween the 25mg/kg GYKI 52466-pretreated and the 4-
P control group (significant decrease in the group that
eceived the AMPA-antagonist), whereas there was no such
ifference between the higher dose pretreatment and the
-AP control group. In the neocortex (Fig. 3), the swelling of
ericapillary astrocytic endfeet (i.e. the increase of the area
c
A
t
o
ccontrol animals (vehicle + 5mg/kg 4-AP), 1 h after the seizure
hout GYKI 52466 pretreatment); (ANOVA, Bonferroni post hoc
ccupied by astrocytic processes) was significantly increased
n the group with lower dose of GYKI 52466-pretreatment
ompared to the vehicle + 4-AP controls, whereas there
as no significant difference between the control and the
0mg/kg GYKI 52466-pretreated groups. In the hippocampus
Fig. 4), no significant alteration can be detected between
he three groups.
. Discussion
he electrophysiological effects of GYKI 52466 are well-
nown, therefore in the present study we focused on the
hort-term behavioural outcomes, changes in gene expres-
ion and ultrastructural pathology, in order to asses the
fficacy of the non-competitive AMPA-receptor antagonist
n convulsions. The GYKI 52466 increased the latency of
he first GTCS (however, without dose-dependent differ-
nce); no GTCS recurrence was observed (if there was
TCS event; only one GTCS per animal was registered
uring the observation). The seizure survival of the pre-
reated animals was 100%, however, in this case there
s no significant change compared to the survival of the
ontrol group animals (80%). As for side-effects of the
MPA-antagonist pretreatment, decrease in the locomo-
or activity (Jakus et al., 2004) and muscle tone were
bserved, likely due to the formerly described central mus-
le relaxant effect (Tarnawa et al., 1989). Probably, this
Blockade of AMPA-receptors 27
Fig. 2 Effect of GYKI 52466 on the c-fos gene expression in the hippocampus. (A—F) Representative immunohistochemical images
illustrating the c-fos and c-fos + parvalbumin (PV) immunolabelled neurons in the hippocampus and dentate gyrus of the experimental
animals. Animals with vehicle + 5mg/kg 4-AP (control) (A and D); 25mg/kg GYKI 52466 + 5mg/kg 4-AP (gyki25) (B and E) and 50mg/kg
GYKI 52466 + 5mg/kg 4-AP (gyki50) (C and F) treatment, respectively (N = 4 per group). Abbrevitations indicate the sectors of the
Ammon’s horn (CA1-3); the dentate gyrus (dg); the hilus of the dentate gyrus (h); and the histological layers of the hippocampus:
stratum oriens (ori), stratum pyramidale (pyr), stratum radiatum (rad), stratum lacunosum-moleculare (lac-mol); respectively.
Rectangular fields note the position of higher magnification samplings. Bar: 250m (A—C); 50m (D—F). Magnification: 40× (A—C);
200× (D—F). G—I. Statistical evaluation of the c-fos (G and H) and c-fos and parvalbumin (I) immunoreactive cell counts pro square
millimetre (sq mm), in the pyramidal layers of the hippocampal areas and in the hilus of the dentate gyrus (G and I) and in the
granular layer of the dentate gyrus (H); comparison of the data from pretreated (with 25 or 50mg/kg GYKI 52466 before 5mg/kg
4-AP, respectively) and the control animals (vehicle + 5mg/kg 4-AP), 1 h after the seizure induction. Asterisks denote the significant
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property can be responsible for the visible reduction of
the tonic seizure component, and the dominance of the
clonic component in the GTCS of the pretreated animals.
Moreover, GYKI 52466 was found to be effective in dif-
ferent models of epilepsy only in doses impairing motor
function (Kubova´ et al., 1997). However, there is a contro-
versy about whether the GYKI 52466 lacks (Tarnawa et al.,
1992; Donevan and Rogawski, 1993) or at least partially has
(Block and Schwarz, 1994; Kubova´ et al., 1997) the effects
of the ‘‘conventional’’ 1,4-benzodiazepines (suspected in
the pharmacological background of the side-effects). Nev-
ertheless, the possibility that DMSO (as vehicle, see later),
eventually potentiates not only the efficacy, but also the
side-effects of GYKI 52466 cannot be entirely excluded.
According to literature data, higher doses are needed for
the moderation of the clonic components, than for the tonic
components (de Sarro et al., 1998). After the intraperitoneal
administration of GYKI 52466, the peak of blood plasma level
is reached between 15 and 45min, then, with a mostly linear
pharmacokinetic fashion, 100—120min after the administra-
tion, the concentration gradually decreases to a near-zero
level. Parallel with this change, the visible anticonvulsive
activity of the drug is maximal between 15 and 60min after
the injection. This period can be characterised with lower
t
b
G
c
sonferroni post hoc test, p < 0.05; S.E.M. is indicated in every
eizure scores (de Sarro et al., 1998), and this is why we
ave focused on the first hour with maximal anticonvulsive
roperties of the GYKI 52466.
To explain the dose-dependent c-fos-IR differences in
he neocortex; we presume (1) different activity states of
he AMPA-receptors, depending on the number of modula-
ory molecules bound by the receptor subunits: GYKI 52466
ay act on more binding sites per every subunit, in a
oncentration-dependent manner (Arai, 2001). In addition
o, we also think that (2) the lower dose of GYKI 52466 is
neffective in the presence of the high glutamate concen-
ration associated with the early seizure activity (Kova´cs et
l., 2003). The GYKI 52466 seemed to be more effective
n delaying the first ictal event, whereas, similarly to some
tudies, the propagation of the seizure activity (Barna et al.,
000) or IEG induction (Berretta et al., 1997) seemed to be
acilitated in the lower dose pretreatment group. Accord-
ng to the literature (Hwa and Avoli, 1991; Barna et al.,
000), the AMPA-receptors are rather involved in the ini-
iation than in the maintenance of seizure (mirrored in our
ehavioural data for increasing seizure latency and reducing
TCS occurrence); whereas the NMDA-receptors play cru-
ial role especially in the maintenance and propagation of
eizure (reflected in the cellular gene expression changes
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Fig. 3 Effect of GYKI 52466 on the capillary area changes and the pericapillary astrocytic process swelling in the neocortex.
(A—C) Representative electron microscopic images illustrating the pericapillary astrocytic endfeet swelling in the neocortex of
the experimental animals. Animals with vehicle + 5mg/kg 4-AP (A); 25mg/kg GYKI 52466 + 5mg/kg 4-AP (B) and 50mg/kg GYKI
52466 + 5mg/kg 4-AP (C) treatment, respectively (N = 4 per group). Capillaries (cap); asterisks denote the surrounding oedematous
astrocytic endfeet. Bar: 2m. Magnification: 5800×. (D) Statistical evaluation of the capillary areas in m2, comparison of the data
from pretreated (25 or 50mg/kg GYKI 52466) and the control animals (vehicle + 5mg/kg 4-AP), 1 h after the seizure induction. (E)
Statistical evaluation of the pericapillary astrocytic endfeet areas in m2, comparison of the data from pretreated (25 or 50mg/kg
GYKI 52466) and the control animals (vehicle + 5mg/kg 4-AP), 1 h after the seizure induction. Asterisks denote the significant
differences (with vs. without GYKI 52466 pretreatment); (ANOVA, Bonferroni post hoc test, p < 0.05; S.E.M. is indicated in every
case).
Fig. 4 Effect of GYKI 52466 on the capillary area changes and the pericapillary astrocytic process swelling in the hippocampus.
(A—C) Representative electron microscopic images illustrating the pericapillary astrocytic endfeet swelling in the hippocampal areas
of the experimental animals. Animals with vehicle + 5mg/kg 4-AP (A); 25mg/kg GYKI 52466 + 5mg/kg 4-AP (B) and 50mg/kg GYKI
52466 + 5mg/kg 4-AP (C) treatment, respectively (N = 4 per group). Capillaries (cap); asterisks denote the surrounding oedematous
astrocytic endfeet. Bar: 2m. Magnification: 5800×. (D) Statistical evaluation of the capillary areas in m2, comparison of the data
from pretreated (25 or 50mg/kg GYKI 52466) and the control animals (vehicle + 5mg/kg 4-AP), 1 h after the seizure induction. (E)
Statistical evaluation of the pericapillary astrocytic endfeet areas in m2, comparison of the data from pretreated (25 or 50mg/kg
GYKI 52466) and the control animals (vehicle + 5mg/kg 4-AP), 1 h after the seizure induction. Asterisks denote the significant
differences (with vs. without GYKI 52466 pretreatment); (ANOVA, Bonferroni post hoc test, p < 0.05; S.E.M. is indicated in every
case).
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4Blockade of AMPA-receptors
and EM morphology alterations). The majority of the AMPA-
receptors can be found in the cells of laminae II—III and
V—VI (Sloper and Powell, 1978; Hicks and Conti, 1996). The
efficacy of the higher dose AMPA-antagonism also refers to
the importance of AMPAergic excitation in these neocortical
strata. The intracortical networks are mainly mediated by
NMDA-receptors, these connections remain active in spite
of the presence of GYKI 52466 (Barna et al., 2000). The
induction of 4-AP-induced synchronous network activity in
the lower neocortical layers is rather dominated by the
excitatory, whilst in the superficial ones, by the inhibitory
components (Yang and Benardo, 2002). At the lower dose of
GYKI 52466, therefore, we suppose (3) a local disequilibrium
between the efficacy of AMPA-receptor antagonism within
the inhibitory population and the overall (rather dominated
by the excitatory cells) population, resulting in the overall
activation status change reflected by the c-fos-IR differ-
ences. The predominance of non-NMDA receptor-mediated
excitatory inputs arising from bursting neurons was shown on
the fast-spiking GABAergic interneurons (Hicks and Conti,
1996); these cells are also strongly excited by thalamic
afferents (Staiger et al., 1996). The inhibitory neurons —
responsible for surrounding inhibition — were less activated
under the influence of GYKI 52466 (significant reduction of
c-fos expression at higher dose of AMPA-receptor antag-
onist; and showing decreasing trend at lower dose with
significant reduction in lamina II). Nevertheless, we found
that these interneurons possessed similar AMPA-receptor
properties to those of the pyramidal cells: the 50mg/kg
dose was needed to significantly decrease the cellular acti-
vation. This local balance-shift may also be complicated
by the slightly different laminar responses to 4-AP (Yang
and Benardo, 2002), since the neocortical PV-containing
GABAergic interneurons constitute a heterogeneous popu-
lation concerning the expression pattern of voltage-gated
K+-channel subunits in the different neocortical laminae
(Chow et al., 1999).
In the hippocampal areas studied, even the lower dose
(25mg/kg) of GYKI 52466 was efficient to reduce the c-
fos immunoreactivity, not only in the parvalbumin-labelled,
but also in the whole c-fos-IR neuronal population, espe-
cially in the granular layer of the dentate gyrus. This fact
emphasises the differences in the receptorial distribution
and spatial separation of excitatory and inhibitory axon sys-
tems in the hippocampus (McBain et al., 1999; Moga et al.,
2002). According to immunostaining data, AMPA-receptors
are concentrated in the outer molecular layer of the dentate
gyrus and in the stratum lacunosum-moleculare of the regio
superior (Molna´r et al., 1993), while NMDA receptors are rel-
atively scarce in the same regions (Kopniczky et al., 2005).
These layers are the main excitatory input areas: the axon
terminals of the perforant path synapse here (Lado et al.,
2002). The prominent contribution of the AMPA-receptors to
the activation of the neuronal circuits is shown by the sig-
nificant reduction of the number of the c-fos-IR cells of the
hippocampal CA1, CA2 and CA3 sectors and in the stratum
granulosum and hilus of the dentate gyrus, even by the lower
(25mg/kg) pretreatment dose.
On the basis of the morphological results, we con-
clude that acute seizures caused the increased swelling
of the astrocytes. Our previous investigations (Fabene
et al., 2006) revealed the importance of brain swelling
a
s
M
i29
n 4-AP seizures: the long-lasting astrocyte swelling was
esponsible for the critical decrease of apparent diffusion
oefficient (ADC) values, as shown by our MRI experiments.
egional differences in astrocytic swelling (Fabene et al.,
006) are likely due to the various astrocytic capacities
or glutamate metabolism, neurotransmission (Bordey and
ontheimer, 2000) and aquaporin-synthesis (Han et al.,
004). The swelling of the astrocytes (Kimelberg, 2004)
bliterates brain extracellular spaces, inhibiting the clear-
nce of transmitters, ions and HCO3− from the extracellular
pace; contributing to and enhancing the cellular dam-
ge (van Gelder et al., 1983); leading to a long-lasting
ecrease in volume transmission (Sykova´, 2005; Fabene et
l., 2006). The current antiepileptic drugs have been shown
o exert their effect on the astrocytes by directly depressing
heir Ca2+-signalling (Tian et al., 2005). The mechanism of
eizure-related astrocyte swelling is likely to be multifac-
orial (Olsson et al., 2006); such as (1) circulatory (Hong
t al., 2004) and (2) metabolic (Briellmann et al., 2005)
hanges due to seizure activity. Alternatively, the astroglial
olume-change may be secondary to (3) the failure of these
ells to manage the consequences of increased neuronal
ctivity (e.g. may also derive from fluid uptake secondary
o the extracellular changes accompanying elevated neu-
onal functioning), thus providing a mechanism reinforcing
eizure per se (Olsson et al., 2006). Literature data are lim-
ted concerning the roles of AMPA-receptor antagonism in
he seizure-related pericapillary astrocyte swelling; whilst
he action of the NMDA-receptor antagonists influencing
he changes of the brain water compartments (Hantzschel
nd Andreas, 1998), or modulating the pericapillary astro-
ytic swelling following injuries (Trout et al., 1995) or
lutamate-administration (Bender et al., 1998) have been
lready described. In our present experiments, the AMPA
lockade was completely ineffective in decreasing seizure-
elated astrocyte swelling—–in the neocortex GYKI 52466
ncreased the swelling of the glia. Other studies (Lees and
eong, 2001) also question the protective effect of GYKI
2466 against seizure-related morphological damage, which
s a contrasting feature with the anticonvulsant efficacy
f this compound (Borowicz et al., 2001; Gulya´s-Kova´cs
t al., 2002). On the other hand, recent results from our
aboratory proved that in the same experimental condi-
ions NMDA blockade with MK801 decreased brain oedema
ignificantly (Za´dor and Weiczner, unpublished), indicating
he differences between roles of the ionotropic receptors,
nd the significance of glutamate. Thus, the overactivation
f NMDA-receptors is suggested mainly in the pathophysi-
logical background of the morphological changes of the
-AP paradigm (Pen˜a and Tapia, 1999). On the basis of
hese results, we conclude that astrocyte swelling is not
ediated by AMPA-receptors, and blockade of the AMPA-
eceptor does not protect against astroglial swelling in
pilepsy. Further investigation should elucidate the role
f astrocytic glutamate receptors, transporters and other
ellular factors (such as aquaporins and connexins) in the
-AP-elicited acute convulsions and the pathophysiology of
strocytic oedema associated with generalised tonic-clonic
eizures.
The effects of DMSO on glutamate responses (Lu and
attson, 2001; Tsvyetlynska et al., 2005) should be taken
nto account in interpreting the results of experiments in
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hich DMSO is used as a solvent (Santos et al., 2003). DMSO,
s a drug vehicle increases the drug concentration into
he extracellular space, but since the BBB permeability is
ncreased, it may also provide an avenue for development of
asogenic oedema (Kleindienst et al., 2006). Taken together,
he oedematous changes in the pericapillary territories may
artially due to the side effects of the vehicle used in this
xperiment. This point can be hardly clarified without using
ther vehicles. Other methods for dissolving GYKI 52466,
uch as using distilled water (Block et al., 1996), physiolog-
cal saline (Kubova´ et al., 1997), or acidic solutions titrated
p to neutral pH (Barna et al., 2000) were proven equally
rreproducible in our laboratory. According to the literature
Lees and Leong, 2001) and to our experience, as well, GYKI
2466 was insoluble in water, and instable in solutions above
H 4. In our next fMRI and EM experiments 2-hydroxypropyl-
-cyclodextrin (HPCD) (Jakus et al., 2004) or CREMOFOR EL
Berretta et al., 1997) as a much more inert vehicle than
MSO is planned to be used. Nevertheless, in another GYKI
2466 study, the HPCD elevated the AMPA/kainate toxic-
ty by increasing the amount of seizure damage (Lees and
eong, 2001).
Summarizing our results, it seems that the main pro-
ective effect of GYKI 52466 is based on the moderate
nhibition of seizure activity only; although the relatively
hort duration of action may also have contributed to
he limited effects of GYKI 52466. This notion-concerning
he low therapeutic index of GYKI 52466- is supported by
he literature (Lees and Leong, 2001; Jakus et al., 2004).
he different extent of participation of AMPA-receptors in
rganising neuronal circuits of neocortex and hippocam-
us in convulsions is reflected by the dissimilar GYKI 52466
fficacy in reducing the seizure-related neuronal activa-
ion. In the hippocampus, cellular activation was relatively
ore dependent upon AMPA-receptors than in the neocor-
ex, but astrocyte swelling was not. We think therefore,
n accordance with the literature (Berretta et al., 1997;
arna et al., 2000; Jakus et al., 2004) that the AMPA-
eceptors appear to be involved primarily in the intiation
f seizures compared with the maintenance and propaga-
ion of cortical seizure activity. Based on the present as
ell as on previous findings (Pen˜a and Tapia, 1999; Lado
t al., 2002; Za´dor and Weiczner, unpublished), antagonists
f NMDA receptors play a more prominent role than antag-
nists of AMPA-receptors in the 4-AP model in preventing
r reducing acute morphological changes such as astrocytic
welling.
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